Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.

Hdl Handle:
http://hdl.handle.net/10147/207682
Title:
Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
Authors:
Ryan, C; Kirby, B; Collins, P; Rogers, S
Affiliation:
Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland., caitrionaryan80@hotmail.com
Citation:
Clin Exp Dermatol. 2009 Oct;34(7):784-8. Epub 2009 Apr 27.
Journal:
Clinical and experimental dermatology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207682
DOI:
10.1111/j.1365-2230.2008.03161.x
PubMed ID:
19438535
Abstract:
AIM: To assess the efficacy and safety profile of adalimumab in patients with severe, recalcitrant chronic plaque psoriasis, and to assess short-term overlapping of other systemic treatment with adalimumab to prevent flaring of disease. METHODS: This was a retrospective study comprising 39 patients with chronic plaque psoriasis treated with adalimumab between October 2005 and January 2008. All had failed treatment with other systemic agents, including biological therapies in 59% of patients. Patients were started on adalimumab 40 mg weekly or fortnightly, as clinically indicated. Severity of psoriasis was assessed by the Psoriasis Area and Severity Index (PASI). Therapeutic response was assessed by 75% improvement on PASI (PASI 75). All adverse events were recorded. RESULTS: Results were analysed separately for those treated with adalimumab only and those on combination treatment. PASI 75 was achieved in 38% (8 of 21 patients at week 16), 62% (13 of 21 patients) at week 24, 69% (9 of 13 patients) at week 48% and 71% (5 of 7 patients) at week 72 in the adalimumab-only group, compared with 56% (5 of 9 patients) at week 16, 50% (4 of 8 patients) at week 24, 80% (4 of 5 patients) at week 48% and 67% (2 of 3 patients) at week 72 in the combined group. Of the 39 patients, 15 (38%) achieved a PASI of 0 at some point in their treatment. Adalimumab was well tolerated; 38% of patients experienced side-effects, which were generally mild. CONCLUSION: Adalimumab was effective in a group of patients with psoriasis refractory to other systemic therapies, including biological treatments, and was well tolerated.
Language:
eng
MeSH:
Adult; Antibodies, Monoclonal/administration & dosage/adverse effects/*therapeutic use; Antibodies, Monoclonal, Humanized; Dermatologic Agents/administration & dosage/adverse effects/*therapeutic use; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Psoriasis/*drug therapy/pathology; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult
ISSN:
1365-2230 (Electronic); 0307-6938 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorRyan, Cen_GB
dc.contributor.authorKirby, Ben_GB
dc.contributor.authorCollins, Pen_GB
dc.contributor.authorRogers, Sen_GB
dc.date.accessioned2012-02-01T10:34:50Z-
dc.date.available2012-02-01T10:34:50Z-
dc.date.issued2012-02-01T10:34:50Z-
dc.identifier.citationClin Exp Dermatol. 2009 Oct;34(7):784-8. Epub 2009 Apr 27.en_GB
dc.identifier.issn1365-2230 (Electronic)en_GB
dc.identifier.issn0307-6938 (Linking)en_GB
dc.identifier.pmid19438535en_GB
dc.identifier.doi10.1111/j.1365-2230.2008.03161.xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207682-
dc.description.abstractAIM: To assess the efficacy and safety profile of adalimumab in patients with severe, recalcitrant chronic plaque psoriasis, and to assess short-term overlapping of other systemic treatment with adalimumab to prevent flaring of disease. METHODS: This was a retrospective study comprising 39 patients with chronic plaque psoriasis treated with adalimumab between October 2005 and January 2008. All had failed treatment with other systemic agents, including biological therapies in 59% of patients. Patients were started on adalimumab 40 mg weekly or fortnightly, as clinically indicated. Severity of psoriasis was assessed by the Psoriasis Area and Severity Index (PASI). Therapeutic response was assessed by 75% improvement on PASI (PASI 75). All adverse events were recorded. RESULTS: Results were analysed separately for those treated with adalimumab only and those on combination treatment. PASI 75 was achieved in 38% (8 of 21 patients at week 16), 62% (13 of 21 patients) at week 24, 69% (9 of 13 patients) at week 48% and 71% (5 of 7 patients) at week 72 in the adalimumab-only group, compared with 56% (5 of 9 patients) at week 16, 50% (4 of 8 patients) at week 24, 80% (4 of 5 patients) at week 48% and 67% (2 of 3 patients) at week 72 in the combined group. Of the 39 patients, 15 (38%) achieved a PASI of 0 at some point in their treatment. Adalimumab was well tolerated; 38% of patients experienced side-effects, which were generally mild. CONCLUSION: Adalimumab was effective in a group of patients with psoriasis refractory to other systemic therapies, including biological treatments, and was well tolerated.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAntibodies, Monoclonal/administration & dosage/adverse effects/*therapeutic useen_GB
dc.subject.meshAntibodies, Monoclonal, Humanizeden_GB
dc.subject.meshDermatologic Agents/administration & dosage/adverse effects/*therapeutic useen_GB
dc.subject.meshDrug Administration Scheduleen_GB
dc.subject.meshDrug Evaluationen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPsoriasis/*drug therapy/pathologyen_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshSeverity of Illness Indexen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.subject.meshYoung Adulten_GB
dc.titleAdalimumab treatment for severe recalcitrant chronic plaque psoriasis.en_GB
dc.contributor.departmentDepartment of Dermatology, St Vincent's University Hospital, Dublin, Ireland., caitrionaryan80@hotmail.comen_GB
dc.identifier.journalClinical and experimental dermatologyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.